Step 2 CK · Internal Medicine · Hematology/Oncology

Thalassemia Trait vs Iron Deficiency & Iron Overload

Name: Thalassemia Trait vs Iron Deficiency & Iron Overload
Creator: Veli Bakalov, MD

Small cells, high counts — and when iron is the wrong answer

Hematology/Oncology·Anemias & Red Cell Disorders·5 min read·9 high-yield points·Reviewed by Veli Bakalov, MD @HemeOncBuddy

Study materialsNo account needed

Card deckActive-recall cards · quick checks · quiz

High-yield

Microcytosis with a high RBC count, normal RDW, normal ferritin, and Mentzer index (MCV ÷ RBC) <13 means thalassemia trait — do not give iron.
β-Thalassemia trait: HbA2 >3.5% ± mildly raised HbF; iron deficiency lowers HbA2, so replete iron before trusting a normal result.
α-Thalassemia trait has a normal adult electrophoresis; confirm with α-globin gene deletion (DNA) testing when planning pregnancy.
HbH disease = 3 deleted α genes (β4 tetramers, chronic hemolysis, splenomegaly); Hb Bart's (γ4) = 4 deleted genes → hydrops fetalis.
Two carriers need genetic counseling: two β-carriers or two cis α-carriers (--/αα, Southeast Asian) carry a 1-in-4 risk of severe disease per pregnancy.
β-Thalassemia major appears at 6–24 months with HbF dominance and extramedullary hematopoiesis; treat with transfusion + chelation, luspatercept, HSCT, or gene therapy.
Cardiac MRI T2* <20 ms detects myocardial iron; iron cardiomyopathy is the leading cause of death in transfusion-dependent thalassemia.
HFE hemochromatosis (transferrin saturation >45%, C282Y homozygous) is treated with phlebotomy to ferritin 50–100 ng/mL.
Chelators: deferoxamine (hearing/vision toxicity, Yersinia), deferasirox (renal and hepatic toxicity), deferiprone (agranulocytosis: ANC weekly for the first 6 months, then less often).

Thalassemia trait or iron deficiency?

The trait pattern. Carriers make many small red cells: an MCV often in the 60s or low 70s fL with near-normal hemoglobin, a normal or high (>5 million/μL) RBC count, a usually normal RDW, target cells (plus basophilic stippling in β-trait), and a normal ferritin. Iron deficiency makes fewer cells, with a high RDW and a ferritin below 30 ng/mL.

Mentzer index. MCV (fL) ÷ RBC count (millions/μL): below 13 favors trait, above 13 favors iron deficiency. It is a screening clue; ferritin and hemoglobin analysis confirm.

Microcytosis: three common look-alikes

Feature	Iron deficiency	β-Thalassemia trait	α-Thalassemia trait (2 genes)
RBC count	Low	Normal or high	Normal or high
RDW	High	Usually normal	Usually normal
Mentzer index	>13	<13	<13
Ferritin	Low (<30 ng/mL)	Normal	Normal
Electrophoresis	Normal; HbA2 may be low	HbA2 >3.5% ± ↑HbF	Normal in adults
Confirmation	Ferritin, response to iron	Electrophoresis once iron-replete	α-Globin gene deletion testing

Managing the carrier. Trait needs no treatment. Iron will not raise the MCV and only adds iron the patient does not need; microcytosis that never budges after "adequate" oral iron while ferritin is normal is a classic clue. Document the diagnosis so no one restarts iron or repeats the workup, and offer carrier counseling before pregnancy.

Confirming the carrier state

β-Thalassemia trait. One abnormal β gene (β-thalassemia minor) raises HbA2 (α2δ2) above 3.5%, typically to 4–6%, sometimes with a mild HbF rise. Common ancestries: Mediterranean, Middle Eastern, South Asian, African.

Iron deficiency suppresses HbA2 and can pull a β-carrier below 3.5%. If ferritin is low, replete iron and repeat electrophoresis — the two often coexist, especially in pregnancy.

α-Thalassemia trait. Two deleted α-globin genes give iron-replete microcytosis with a normal adult electrophoresis. It remains a diagnosis of exclusion unless the answer matters (preconception, pregnancy, a carrier partner); then α-globin gene deletion (DNA) testing confirms it. One-gene silent carriers have near-normal indices. Deletions may be cis (--/αα, common in Southeast Asia) or trans (-α/-α, typical in African ancestry).

HbH disease. With three genes deleted (--/-α), excess β chains form unstable β4 tetramers (HbH, visible on electrophoresis) that precipitate as golf-ball inclusions on brilliant cresyl blue stain. Expect lifelong microcytic hemolytic anemia with jaundice, splenomegaly, and gallstones, and flares with infection or oxidant drugs that may need transfusion.

Hb Bart's hydrops fetalis. With all four genes deleted (--/--), γ4 tetramers (Hb Bart's) bind oxygen so tightly that tissues starve. The fetus develops high-output failure and hydrops and usually dies in utero or at birth without intrauterine transfusion; the mother risks preeclampsia and polyhydramnios.

Identify a carrieriron-replete microcytosis before or early in pregnancy → electrophoresis ± α-globin DNA testing
Test the partnersame workup
Both carriersgenetic counseling: two β-carriers or two cis α-carriers each carry a 1-in-4 risk per pregnancy of severe disease
Prenatal diagnosisCVS or amniocentesis, or preimplantation genetic testing with IVF

A trans α-carrier (-α/-α) never passes a double-deleted chromosome, so Hb Bart's hydrops requires two cis carriers.

β-Thalassemia major

Presentation. In β0/β0 disease (Cooley anemia) infants are well at birth, because fetal hemoglobin needs no β chains, then develop severe microcytic hemolytic anemia at 6–24 months. Unpaired α chains precipitate in erythroid precursors (ineffective erythropoiesis); marrow expansion and extramedullary hematopoiesis cause hepatosplenomegaly, frontal bossing, maxillary overgrowth, and a hair-on-end skull film. Electrophoresis shows mostly HbF with HbA absent or trace.

Treatment. Transfuse every 2–5 weeks to keep the pretransfusion hemoglobin near 9–10.5 g/dL, which permits growth and suppresses marrow expansion; start chelation after about 10–20 units or when ferritin exceeds 1000 ng/mL; give folic acid. Luspatercept, an erythroid maturation agent, lowers transfusion needs. Matched-sibling HSCT, ideally in childhood, is curative, and gene therapy — betibeglogene autotemcel (β-globin gene addition) or exagamglogene autotemcel (BCL11A editing that reactivates HbF) — can end transfusion dependence.

Splenectomy for hypersplenism raises the risk of overwhelming sepsis and thrombosis; vaccinate against encapsulated organisms first.

Iron overload

Sources. The body cannot excrete iron, and each red cell unit adds about 200–250 mg. In HFE hemochromatosis (autosomal recessive; usually C282Y homozygosity in Northern Europeans) low hepcidin leaves ferroportin active, so gut absorption goes unchecked.

Organ damage. Cardiomyopathy and arrhythmias are the main killer in transfused thalassemia. Liver iron causes cirrhosis and hepatocellular carcinoma; endocrine deposits cause diabetes, hypogonadism, hypothyroidism, and growth failure; skin turns bronze. Hemochromatosis adds 2nd/3rd MCP arthropathy with chondrocalcinosis and infection by siderophilic organisms such as Vibrio vulnificus.

Measuring the burden. Ferritin misleads because it is also an acute-phase reactant. Cardiac MRI T2* below 20 ms indicates myocardial iron and below 10 ms severe loading, often before the ejection fraction falls; MRI also quantifies liver iron.

Hemochromatosis. Screen with transferrin saturation (>45%) and ferritin, then HFE genotyping; test first-degree relatives. Ferritin >1000 ng/mL or abnormal liver enzymes → stage fibrosis; cirrhosis requires HCC surveillance. Phlebotomize weekly (500 mL removes about 200–250 mg iron) to a ferritin of 50–100 ng/mL, then continue maintenance phlebotomy. Avoid iron and vitamin C supplements and raw shellfish; limit alcohol.

Iron chelators for transfusional overload

Drug	Route	Key toxicity	Monitoring / niche
Deferoxamine	SC or IV infusion	Ototoxicity, retinopathy, Yersinia infection	Hearing and eye exams; continuous IV for cardiac crises
Deferasirox	Oral, once daily	Renal and hepatic toxicity, GI bleeding	Creatinine and LFTs
Deferiprone	Oral	Agranulocytosis	ANC weekly for 6 months, then every 2 weeks for 6 months, then every 2 to 4 weeks; best for cardiac iron

Anemic, transfusion-dependent patients cannot be phlebotomized — they need chelation. Decompensated iron cardiomyopathy calls for continuous IV deferoxamine plus deferiprone.